Signal Transduction and Targeted Therapy
Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial
Randomised trial in 250 peopleObesity
Papers by Ben Li
2 results
- ADA Scientific Sessions 2025 Abstract
Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity
Trial in peopleInterventions